MCM2 and plasma cell myeloma: The prognostic value of MCM2 was confirmed in pancreatic cancer, lung cancer, multiple myeloma, and oral cancer (Ramnath et al., 2001; Torres-Rendon et al., 2009; Deng et al., 2020; Quan et al., 2020).